FDA Fast Track Designation Sends AKTX Stock Up 30%

AKTX stock

It’s not easy to get approval from the FDA. There are steps to follow, standards to meet. Sometimes, companies fail. But Akari Therapeutics (NASDAQ:AKTX) is not one of them, receiving Fast Track approval from the federal agency this week. On the news, AKTX stock jumped, currently up nearly 40%.

AKTX Stock Skyrockets 30% on FDA Fast Track Designation

Today, August 14, United Kingdom-based Akari Therapeutics announced it has been given a “Fast Track” designation by the United States FDA for its treatment of stem-cell transplant-associated thrombotic microangiopathy in pediatric patients. Of course, any approval from the ...

Read The Full Article On MicroSmallCap.com

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.